{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-017991","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.307933+00:00","generated_at":"2026-06-08T16:38:46.312258+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Olema reports Q3 net loss $21.5M, cash $276.9M; OPERA-01 Phase 3 on track","bullets":["Net loss $21.5M vs $22.7M YoY; cash, equivalents and marketable securities $276.9M.","R&D expenses $19.5M GAAP ($16.7M non-GAAP) as Phase 3 palazestrant trial advances.","OPERA-01 Phase 3 monotherapy trial site activation ongoing, first patient expected Q4 2023.","New palazestrant combination data with CDK4/6 inhibitors to be presented at SABCS Dec 2023.","Appointed Scott Garland to board; completed financing up to $180M (equity + credit facility)."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-017991","json":"https://secwatch.observer/filing/0001558370-23-017991.json","markdown":"https://secwatch.observer/filing/0001558370-23-017991.md","text":"https://secwatch.observer/filing/0001558370-23-017991.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000155837023017991/0001558370-23-017991-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000155837023017991/olma-20231107x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T16:38:46.312258+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"744caffc77d8ec9bdaec1aad06735ec30273737c","claim":"Olema Pharmaceuticals, Inc. reported quarter ended September 30, 2023 results: net income $21.5 million.","evidence_excerpt":"Net loss for the quarter ended September 30, 2023, was $21.5 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750284/000155837023017991/0001558370-23-017991-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2023"},{"label":"Net income","value":"$21.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}